Bowel Perforation after Erlotinib Treatment in a Patient with Non-Small Cell Lung Cancer

Erlotinib is accepted as a standard second-line chemotherapeutic agent in patients with non-small cell lung cancer who are refractory or resistant to first-line platinum-based chemotherapy. There has been no previous report of bowel perforation with or without gastrointestinal metastases related to...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Cheon, Yun-Hong, Kim, Moon Jin, Kang, Min Gyu, Kim, Hee Jin, Lee, Sang Su, Kim, Cha Young, Jeon, Dae-Hong, Kim, Yu Eun, Lee, Gyeong-Won
Médium: Artigo
Jazyk:Inglês
Vydáno: Yonsei University College of Medicine 2011
Témata:
Case Report
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3104451/
https://ncbi.nlm.nih.gov/pubmed/21623617
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3349/ymj.2011.52.4.695
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky